Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
208.3 EUR | +2.41% | +3.84% | -13.03% |
Apr. 23 | SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating | ZD |
Apr. 22 | Sartorius Stedim: in the red with brokerage comments | CF |
Sales 2024 * | 2.94B 3.14B | Sales 2025 * | 3.35B 3.58B | Capitalization | 20.27B 21.67B |
---|---|---|---|---|---|
Net income 2024 * | 343M 367M | Net income 2025 * | 459M 491M | EV / Sales 2024 * | 7.66 x |
Net Debt 2024 * | 2.27B 2.42B | Net Debt 2025 * | 2.15B 2.3B | EV / Sales 2025 * | 6.69 x |
P/E ratio 2024 * |
57.7
x | P/E ratio 2025 * |
41.7
x | Employees | 10,493 |
Yield 2024 * |
0.36% | Yield 2025 * |
0.53% | Free-Float | 31.97% |
Latest transcript on Sartorius Stedim Biotech
1 day | +2.41% | ||
1 week | -0.62% | ||
Current month | -21.19% | ||
1 month | -23.19% | ||
3 months | -8.44% | ||
6 months | +25.48% | ||
Current year | -13.03% |
Managers | Title | Age | Since |
---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 48 | 19-03-25 |
Chairman | 59 | 07-06-28 | |
Chief Tech/Sci/R&D Officer | 59 | 09-04-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Henri Riey
BRD | Director/Board Member | 62 | 07-06-28 |
Chairman | 59 | 07-06-28 | |
Susan Dexter
BRD | Director/Board Member | 67 | 15-04-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.42% | 18 M€ | +3.79% | - | |
0.35% | 5 M€ | +4.56% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 208.3 | +2.41% | 63,774 |
24-04-25 | 203.4 | -2.35% | 89,724 |
24-04-24 | 208.3 | -0.19% | 76,624 |
24-04-23 | 208.7 | +6.21% | 106,382 |
24-04-22 | 196.5 | -2.04% | 113,309 |
Real-time Euronext Paris, April 26, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.03% | 21.2B | |
-2.31% | 185B | |
-3.20% | 105B | |
-5.04% | 66.59B | |
+0.20% | 54.66B | |
+17.29% | 47.78B | |
+4.06% | 41.26B | |
+2.36% | 26.95B | |
+2.07% | 26.37B | |
+12.96% | 24.8B |
- Stock Market
- Equities
- DIM Stock